Look for Drugs and Conditions

MACITENTAN

MACITENTAN

It is an endothelin receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH). Macitentan is a dual ERA, meaning that it acts as an antagonist of two endothelin (ET) receptor subtypes, ETA and ETB. However, macitentan has a 50-fold increased selectivity for the ETA subtype compared to the ETB subtype.

Indications

Pulmonary Arterial Hypertension (WHO group1).


Dosage

Oral; 10mg once daily.


Contra-Indications

Pregnancy.


Special Precautions

Paediatric: Safety and efficacy in pediatric patients have not been established. Pregnancy: contraindicated, Female patients of reproductive potential must have a negative pregnancy test prior to starting treatment, monthly during treatment, and one month after discontinuation of treatment. Lactation: it is not known whether it is excreted into the human breast milk, advise women not to breastfeed during treatment Elderly: No overall differences in safety or effectiveness have been observed between elderly and other adult patients.


Side Effects

Anemia, Nasopharyngitis/pharyngitis, Bronchitis, Headache, Influenza, Urinary tract infection, hypersensitivity reactions (angioedema, pruritus and rash), nasal congestion, Elevations of liver aminotransferases (ALT, AST), edema/fluid retention, decrease in hemoglobin, decrease sperm count.


Drug Interactions

Strong CYP3A4 Inducers like rifampicin, Strong CYP3A4 Inhibitors like ketoconazole.


Other Brands With Same Generic
Brand Name Manufactured by
MACIKAD LUPIN LTD.
MACITENT MSN Lab
OPSUMIT ROCHE
OPSUTAN CIPLA
Ad 5